期刊文献+

Neural stem cell therapy for brain disease 被引量:5

下载PDF
导出
摘要 Brain diseases, including brain tumors, neurodegenerative disorders, cerebrovasculardiseases, and traumatic brain injuries, are among the major disordersinfluencing human health, currently with no effective therapy. Due to the lowregeneration capacity of neurons, insufficient secretion of neurotrophic factors,and the aggravation of ischemia and hypoxia after nerve injury, irreversible lossof functional neurons and nerve tissue damage occurs. This damage is difficult torepair and regenerate the central nervous system after injury. Neural stem cells(NSCs) are pluripotent stem cells that only exist in the central nervous system.They have good self-renewal potential and ability to differentiate into neurons,astrocytes, and oligodendrocytes and improve the cellular microenvironment.NSC transplantation approaches have been made for various neurodegenerativedisorders based on their regenerative potential. This review summarizes anddiscusses the characteristics of NSCs, and the advantages and effects of NSCs inthe treatment of brain diseases and limitations of NSC transplantation that need tobe addressed for the treatment of brain diseases in the future.
出处 《World Journal of Stem Cells》 SCIE 2021年第9期1278-1292,共15页 世界干细胞杂志(英文版)(电子版)
  • 相关文献

参考文献9

二级参考文献206

  • 1Davie CA. A review of Parkinson’s disease. Br Med Bull 2008; 86:109-127 [PMID: 18398010 DOI: 10.1093/bmb/ldn013].
  • 2Dauer W, Przedborski S. Parkinson’s disease: mechanisms andmodels. Neuron 2003; 39: 889-909 [PMID: 12971891 DOI:10.1016/S0896-6273(03)00568-3].
  • 3Cheon SM, Chan L, Chan DK, Kim JW. Genetics of Parkinson’sdisease - a clinical perspective. J Mov Disord 2012; 5: 33-41 [PMID:24868412 DOI: 10.14802/jmd.12009].
  • 4Lesage S, Brice A. Parkinson’s disease: from monogenic forms togenetic susceptibility factors. Hum Mol Genet 2009; 18: R48-R59[PMID: 19297401 DOI: 10.1093/hmg/ddp012].
  • 5Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinicaldiagnosis of Lewy body Parkinson’s disease. Neurology 2001; 57:1497-1499 [PMID: 11673599 DOI: 10.1212/WNL.57.8.1497].
  • 6Lang AE, Lozano AM. Parkinson’s disease. First of two parts. NEngl J Med 1998; 339: 1044-1053 [PMID: 9761807 DOI: 10.1056/NEJM199810083391506].
  • 7Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. NEngl J Med 1998; 339: 1130-1143 [PMID: 9770561 DOI: 10.1056/NEJM199810153391607].
  • 8Jankovic J. Parkinson’s disease: clinical features and diagnosis. JNeurol Neurosurg Psychiatry 2008; 79: 368-376 [PMID: 18344392DOI: 10.1136/jnnp.2007.131045].
  • 9Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, JonesE. Alzheimer’s disease. Lancet 2011; 377: 1019-1031 [PMID:21371747 DOI: 10.1016/S0140-6736(10)61349-9].
  • 10Finch CE, Morgan TE. Systemic inflammation, infection, ApoEalleles, and Alzheimer disease: a position paper. Curr Alzheimer Res2007; 4: 185-189 [PMID: 17430245 DOI: 10.2174/156720507780362254].

共引文献204

同被引文献17

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部